← Back to Search

Intraocular Lens

enVista Beyond EY IOL for Cataract

N/A

Waitlist Available

Research Sponsored by Bausch & Lomb Incorporated

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 120 to day 180 after second eye implantation

Awards & highlights

Study Summary

This trial is testing a new type of lens called the Bausch + Lomb enVista Beyond Hydrophobic Acrylic Extended Depth of Focus Intraocular Lens in people who will have it put

Who is the study for?

This trial is for individuals planning to undergo cataract extraction and who wish to receive a new type of lens implant called the enVista Beyond IOL. Specific eligibility criteria are not provided, but typically participants should be in good general health with no other eye diseases.Check my eligibility

What is being tested?

The study compares two types of intraocular lenses (IOLs): the new enVista Beyond Hydrophobic Acrylic Extended Depth of Focus IOL and the established TECNIS monofocal IOL. Participants will have one of these lenses implanted during cataract surgery.See study design

What are the potential side effects?

While specific side effects are not listed, common risks associated with IOL implants include inflammation, infection, bleeding, swelling, detachment of retina or lens dislocation. Individual experiences may vary.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 120 to day 180 after second eye implantation

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 120 to day 180 after second eye implantation

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 120 to day 180 after second eye implantation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Mean Monocular Photopic Distance Corrected Intermediate Visual Acuity (DCIVA) of first implanted eyes at Post-Operative Visit 4.

Mean monocular best-corrected distance visual acuity (BCDVA) (logMAR) of first implanted eyes at Post-Operative Visit 4.

Median Monocular Photopic Distance Corrected Intermediate Visual Acuity (DCIVA) of first implanted eyes at Post-Operative Visit 4.

+2 more

Secondary outcome measures

Mean monocular photopic distance-corrected near visual acuity (DCNVA) of first implanted eyes at Post-Operative Visit 4.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: enVista Beyond EY IOLExperimental Treatment1 Intervention

Subjects implanted with enVista Beyond Extended Depth of Focus (EDF) Intraocular Lens (IOL) Model EY

Group II: TECNIS 1-Piece monofocal IOLActive Control1 Intervention

Subjects implanted with TECNIS 1-Piece monofocal IOL

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Bausch & Lomb IncorporatedLead Sponsor

251 Previous Clinical Trials

57,195 Total Patients Enrolled

47 Trials studying Cataract

15,779 Patients Enrolled for Cataract

Anya LoncaricStudy DirectorBausch & Lomb Incorporated

39 Previous Clinical Trials

20,607 Total Patients Enrolled

5 Trials studying Cataract

2,028 Patients Enrolled for Cataract

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

At how many sites is this medical trial currently being conducted?

"At the moment, this medical investigation is enrolling participants at 11 diverse locations. These include cities like Dallas, Montréal, and Calgary among others. Opting for a site in close proximity to your residence would help reduce travel burdens should you decide to take part."

Answered by AI

Are new patients currently being enrolled in this ongoing clinical trial?

"The clinical trial listed on clinicaltrials.gov is no longer seeking participants. Although this particular study, initially posted on April 1st, 2024 and last revised on March 20th, 2024, has reached its enrollment capacity, there are currently 116 other trials actively recruiting new candidates."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF Intraocular Lens in Subjects Undergoing Cataract Extraction

2024. "Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF Intraocular Lens in Subjects Undergoing Cataract Extraction". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06333015.

All > Intraocular Lens > Cataract